Averill Julianne 4

What Happened

• Julianne Averill, a director of Biomea Fusion, was granted a derivative award on 2026-06-10 covering 173,711 shares. The reported price is $0.00, indicating no cash was paid at grant and this is an equity award/option rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-10; Form 4 filed 2026-06-12 (timely filing).
• Grant: 173,711 shares reported as a derivative award (code A); reported price $0.00.
• Shares owned after transaction: not specified in this Form 4.
• Footnote: the underlying shares will vest in full upon the earlier of (i) the one-year anniversary of the grant or (ii) immediately prior to the issuer’s next annual meeting, subject to continued service.
• No indication of immediate sale, tax withholding, 10b5-1 plan, or late filing in this report.

Context

• This is a compensation-related equity grant to a director. Because it’s a derivative award that vests over time, there was no immediate cash transaction or stock sale. Such grants are common for board compensation and do not by themselves indicate buying or selling sentiment.